With the continuing demand for economic and clinical evidence to differentiate innovative therapies from existing agents, manufacturers need to take advantage of real world evidence earlier to guide their development plans.
Join our featured speaker, Dr. Tommy Bramley, for a complimentary webinar focusing on real world evidence examples where data has been gathered, analyzed, and leveraged successfully throughout the development process. Learn how various data and methods have been used to uncover information that can be strategically relevant and beneficial for the success of a manufacturer’s product.
See practical examples of how this can work:
Characterize the target patient population and evaluate how employing different inclusion / exclusion criteria may impact the population size, as well as the number of patients eligible for inclusion in randomized clinical trials (RCTs)
Describe current real world treatment patterns and outcomes to inform selection of RCT comparators, endpoints and targeted line(s) of therapy
Test product attributes relative to current standard of care to assess potential value and identify key value drivers
Estimate how target patient population(s) may change over time based on patient demographics and the introduction of other interventions
Tommy J. Bramley, RPh, PhD, Senior Vice President, Scientific Consulting, Xcenda
Thomas Bramley joined Xcenda in 2001 and is now Senior Vice President of Scientific Consulting. Dr. Bramley has over 10 years of experience specializing in health economics and outcome research and product value diagnostics to support payer marketing strategies. He has provided strategic and research consulting for major Pharmaceutical and biotechnology firms as well as small Pharmaceutical and medical device firms.
Dr. Bramley has participated in the design and development of more than 100 economic models, he has managed or provided input on well over 200 outcomes research and strategy engagements. Dr. Bramley has been an invited speaker at many national conferences and has authored numerous peer-reviewed articles.
Dr. Bramley received the American College of Gastroenterology Governor’s Award for Excellence in Clinical Research at the 2005 conference and was selected as Xcenda’s nominee for AmerisourceBergen’s Specialty Group 2008 Vision Award.
Dr. Bramley received his Bachelor of Science in Pharmacy from Drake University in 1997 and his Doctor of Philosophy in Pharmaceutical and Health Outcome Sciences from the University of South Carolina in 2001.
Who Should Attend?
Professionals from pharmaceutical, biotech, or medical device companies with responsibilities in:
- Medical Affairs
- Real World Evidence
- Data Analytics
- Market Access
- Reimbursement CER
- Data Management
- Publication Planning
- Clinical Operations
Xcenda is a strategic consulting firm with 20 years of experience applying real-world expertise in health economics and outcomes research, reimbursement, health policy, market research, and market access strategy. We support global Pharmaceutical companies as well as emerging pre-commercialization phase firms with challenges such as developing an evidence package to optimize access in key global markets, predicting product performance, and identifying reimbursement strategies and programs to maximize patient access. From development through market maturity, Xcenda helps manufacturers identify, demonstrate, and deliver their brand’s value proposition to key healthcare stakeholders.
Xcenda is backed by an even wider breadth of healthcare knowledge and partnerships through AmerisourceBergen Corporation (NYSE: ABC), one of the world’s largest Pharmaceutical services companies. Xcenda’s strategic consulting services support the design of patient support services and specialty distribution programs to improve product access and adherence at every stage of its life cycle.